You are here

Journal of clinical oncology : official journal of the American Society of Clinical Oncology DOI:10.1200/JCO.2010.32.6421

mRNA expression signature of Gleason grade predicts lethal prostate cancer.

Publication TypeJournal Article
Year of Publication2011
AuthorsPenney, KL, Sinnott, JA, Fall, K, Pawitan, Y, Hoshida, Y, Kraft, P, Stark, JR, Fiorentino, M, Perner, S, Finn, S, Calza, S, Flavin, R, Freedman, ML, Setlur, S, Sesso, HD, Andersson, SO, Martin, N, Kantoff, PW, Johansson, JE, Adami, HO, Rubin, MA, Loda, M, Golub, TR, Andrén, O, Stampfer, MJ, Mucci, LA
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume29
Issue17
Pages2391-6
Date Published2011/06/10
ISSN0732-183X
Abstract

Prostate-specific antigen screening has led to enormous overtreatment of prostate cancer because of the inability to distinguish potentially lethal disease at diagnosis. We reasoned that by identifying an mRNA signature of Gleason grade, the best predictor of prognosis, we could improve prediction of lethal disease among men with moderate Gleason 7 tumors, the most common grade, and the most indeterminate in terms of prognosis.

URLhttp://www.jco.org/cgi/pmidlookup?view=long&pmid=21537050
DOI10.1200/JCO.2010.32.6421
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/21537050?dopt=Abstract